Download MendeleyDesign, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells.
Shiokawa, Z., Hashimoto, K., Saito, B., Oguro, Y., Sumi, H., Yabuki, M., Yoshimatsu, M., Kosugi, Y., Debori, Y., Morishita, N., Dougan, D.R., Snell, G.P., Yoshida, S., Ishikawa, T.(2013) Bioorg Med Chem 21: 7938-7954
- PubMed: 24169315
- DOI: https://doi.org/10.1016/j.bmc.2013.09.067
- Primary Citation of Related Structures:
4MTI, 4MU7 - PubMed Abstract:
We previously reported octahydropyrrolo[1,2-a]pyrazine derivative 2 (T-3256336) as a potent antagonist for inhibitors of apoptosis (IAP) proteins. Because compound 2 was susceptible to MDR1 mediated efflux, we developed another scaffold, hexahydropyrazino[1,2-a]indole, using structure-based drug design. The fused benzene ring of this scaffold was aimed at increasing the lipophilicity and decreasing the basicity of the scaffold to improve the membrane permeability across MDR1 expressing cells. We established a chiral pool synthetic route to yield the desired tricyclic chiral isomers. Chemical modification of the core scaffold led to a representative compound 50, which showed strong inhibition of IAP binding (X chromosome-linked IAP [XIAP]: IC50 23 nM and cellular IAP [cIAP]: IC50 1.1 nM) and cell growth inhibition (MDA-MB-231 cells: GI50 2.8 nM) with high permeability and low potential of MDR1 substrate.
Organizational Affiliation:
Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: zenyu.shiokawa@takeda.com.
